Eliquis Becoming Most Popular Blood Thinner
For years, Johnson & Johnson’s anticoagulant, Xarelto was the market leader of blood thinners. Now, Eliquis, marketed by Bristol-Myers Squibb and Pfizer is leading Xarelto based upon prescription data. Eliquis brought in 667,000 prescriptions last September while Xarelto had 711,000. This isn’t a surprise since Bristol-Myers Squibb and Pfizer spent double the amount of Johnson
Read More
New Eliquis MDL
On February 7th, there was an important trial update for the case against Bristol-Myers Squibb and Pfizer concerning their blood thinner, Eliquis. Eliquis is responsible for the injury and death of hundreds of people. At The Michael Brady Lynch Firm, we are trying to put a stop to it by holding these large pharmaceutical companies
Read More
The Michael Brady Lynch Firm on the Forefront of Eliquis Litigation
On January 26 in Miami, Florida, the US Judicial Panel on Multidistrict Litigation (JPMDL) heard a motion to create a new Eliquis multidistrict litigation in New York. Currently, this litigation is comprised of 34 related actions filed in 12 different federal districts. The Michael Brady Lynch firm is seeking justice for our clients who took
Read More